Optimizing Treatment Management of Trastuzumab Deruxtecan in Clinical Practice of Breast Cancer

    August 2022 in “ ESMO Open ”
    Hope S. Rugo, Giampaolo Bianchini, Javier Cortés … Michael Untch
    Studysummary This review discusses managing common and notable adverse events associated with the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-positive unresectable/metastatic breast cancer and reports no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on esmoopen.com →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Prevention And Management Of Dermatological Toxicities Related To Anticancer Agents: ESMO Clinical Practice Guidelines Annals of Oncology · 2020
    2. Prevention and Treatment of Chemotherapy-Induced Alopecia Dermatology practical & conceptual · 2020
    3. Scalp Cooling to Prevent Chemotherapy-Induced Alopecia Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia · 2020
    4. Pathobiology of Chemotherapy-Induced Hair Loss The Lancet Oncology · 2013